Hi. I've posted something like this before, but w
Post# of 153638
There has historically almost never been a buyout by one pharma company buying another at a large multiple of the market cap. Two times the cap has happened, and perhaps three, but I think not.
None of us want to sell the company at a buck a share or less. The only way we can get a better price is to build the share price first, then sell. That can mean partnerships/licensing deals, good test results, and/or a BTD, accelerated approval, or conditional approval. Jack up the share price, then sell for the market cap times two, maybe.
Jay knows all this, and I feel very sure he will want to sell when the time comes.
Which is not now.

